Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.1K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

823
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
823
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

952
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
952

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of bilateral disease and choroidal neovascularisation in punctate inner choroiditis.

The British journal of ophthalmology·2026
Same author

Evidence and Consensus Based Guidelines for Imaging in Tubercular Choroiditis. Multimodal imaging in Uveitis (MUV) Taskforce: Report 17.

Ophthalmology. Retina·2026
Same author

Antiadalimumab Antibodies in Patients With Inflammatory Ocular Diseases: Incidence and Clinical Outcomes.

American journal of ophthalmology·2026
Same author

Evidence and Consensus-Based Guidelines in Vogt-Koyanagi-Harada Disease. Multimodal Imaging in Uveitis (MUV) Taskforce Report 16.

Ophthalmology. Retina·2026
Same author

Deconstructing White Dot Syndromes-Multimodal Imaging in Uveitis (MUV) Taskforce: Report 11.

American journal of ophthalmology·2026
Same author

Evidence and Consensus-Based Imaging Guidelines in Cytomegalovirus Retinitis: Multimodal Imaging in Uveitis (MUV) Task Force - Report 15.

Ophthalmology. Retina·2026

Related Experiment Video

Updated: Nov 18, 2025

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.6K

Uveitis for the non-ophthalmologist.

Bryn M Burkholder1, Douglas A Jabs2,3

  • 1Wilmer Eye Institute, Department of Ophthalmology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA bburkho1@jhmi.edu.

BMJ (Clinical Research Ed.)
|February 4, 2021
PubMed
Summary
This summary is machine-generated.

Uveitis, or eye inflammation, is classified as infectious or non-infectious. Treatment for infectious uveitis targets the specific organism, while non-infectious uveitis is primarily managed with corticosteroids and immunosuppressants.

More Related Videos

A Surgical Approach for Optic Nerve Crush in a Rabbit Model
06:15

A Surgical Approach for Optic Nerve Crush in a Rabbit Model

Published on: July 8, 2025

876
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.6K

Related Experiment Videos

Last Updated: Nov 18, 2025

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.6K
A Surgical Approach for Optic Nerve Crush in a Rabbit Model
06:15

A Surgical Approach for Optic Nerve Crush in a Rabbit Model

Published on: July 8, 2025

876
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.6K

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Uveitis encompasses diverse intraocular inflammatory diseases.
  • Classified into infectious and non-infectious categories.
  • Non-infectious uveitis is immune-mediated, either systemic or eye-limited.

Purpose of the Study:

  • To outline the classification and diagnostic approaches for uveitic entities.
  • To describe current therapeutic strategies for infectious and non-infectious uveitis.
  • To emphasize the importance of multidisciplinary care in managing complex cases.

Main Methods:

  • Diagnosis involves medical history, clinical examination, ocular imaging, and laboratory tests.
  • Treatment for infectious uveitis is pathogen-specific.
  • Non-infectious uveitis treatment starts with corticosteroids, progressing to immunosuppressants if necessary.

Main Results:

  • Ophthalmologists diagnose uveitis using a comprehensive approach.
  • Corticosteroids are the first-line treatment for non-infectious uveitis.
  • Systemic immunosuppressive therapy is reserved for severe or refractory cases.

Conclusions:

  • Effective management of uveitis requires accurate diagnosis and tailored treatment.
  • Coordination between ophthalmologists and other specialists is crucial for optimal patient outcomes.
  • Current treatment paradigms address both infectious and immune-mediated intraocular inflammation.